Muristek
Among patients with major depressive disorder (MDD), less than 40% achieve clinical remission after an initial treatment with an antidepressant. For those who do not improve after 2 or more antidepressant treatment trials (ie, treatment-resistant depression), the rates of remission are less than 20%. Because each of these failed treatments translates to several months of prolonged illness, a series of multiple ineffective treatments contributes to the substantial disability and morbidity associated with MDD, as well as to an increase in the suicide risk. There is a critical need for validated biomarkers to predict treatment response and to guide the selection of the most effective next-step antidepressant treatments (ie, using another antidepressant; another treatment, such as psychotherapy or transcranial magnetic stimulation; or a combination). Promising results in this direction have been reported with clinical, electroencephalographic, and neuroimaging variables, but none of these approaches has yet been prospectively validated or translated into clinically useful tests.
Most Read